A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin-0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis

被引:13
作者
Hosseini, Kamran [1 ]
Lindstrom, Richard L. [2 ,3 ]
Foulks, Gary [4 ]
Nichols, Kelly K. [5 ]
机构
[1] InSite Vis, Alameda, CA USA
[2] Minnesota Eye Consultants, Minneapolis, MN USA
[3] Univ Minnesota, Sch Med, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA
[4] Univ Louisville, Sch Med, Dept Ophthalmol & Vis Sci, Louisville, KY 40292 USA
[5] Univ Alabama Birmingham, Sch Optometry, Birmingham, AL 35294 USA
来源
CLINICAL OPHTHALMOLOGY | 2016年 / 10卷
关键词
blepharitis; dexamethasone; azithromycin; eyelid inflammation;
D O I
10.2147/OPTH.S110739
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the clinical efficacy and safety of a 1% azithromycin-0.1% dexamethasone combination in DuraSite ("combination") compared to 0.1% dexamethasone in DuraSite, 1% azithromycin in DuraSite, and vehicle in the treatment of subjects with blepharitis. Materials and methods: This was a Phase III, double-masked, vehicle-controlled, four-arm study in which 907 subjects with blepharitis were randomized to combination (n=305), 0.1% dexamethasone (n=298), 1% azithromycin (n=155), or vehicle (n=149). Ten study visits were scheduled: screening visit, days 1 and 4 (dosing phase) and 15, and months 1-6 (follow-up phase). On day 1, subjects applied one drop of the study drug to the eyelid of the inflamed eye(s) twice daily, and continued with twice-daily dosing for 14 days. After completing 14 days of dosing, subjects were followed for 6 months for efficacy and safety. Results: A total of 57 subjects (6.3%) had complete clinical resolution at day 15: 25 (8.2%), 17 (5.7%), 8 (5.2%), and 7 (4.7%) subjects in the combination-, 0.1% dexamethasone-, 1% azithromycin-, and vehicle-treatment groups, respectively. The combination was superior to 1% azithromycin and vehicle alone, but not to 0.1% dexamethasone alone. Mean composite (total) clinical sign and symptom scores improved in all four treatment groups during the post-treatment evaluation phase for the intent-to-treat population, but outcomes were superior when a drop containing 0.1% dexamethasone was utilized. Clinical response was noted as early as day 4, and persisted as long as 6 months. Most adverse events were considered mild in severity and not related to the study drug. Conclusion: A higher percentage of subjects in the combination group achieved complete clinical resolution of the signs and symptoms of blepharitis at day 15 than with 1% azithromycin and vehicle, but outcomes were similar to treatment with 0.1% dexamethasone alone. The combination was well tolerated.
引用
收藏
页码:1495 / 1503
页数:9
相关论文
共 16 条
[1]   Ocular Surface Distribution and Pharmacokinetics of a Novel Ophthalmic 1% Azithromycin Formulation [J].
Akpek, Esen Karamursel ;
Vittitow, Jason ;
Verhoeven, Rozemarijn S. ;
Brubaker, Kurt ;
Amar, Thierry ;
Powell, Kendall D. ;
Boyer, Jose L. ;
Crean, Christopher .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2009, 25 (05) :433-439
[2]   Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits [J].
Amar, Thierry ;
Caillaud, Thierry ;
Elena, Pierre-Paul .
CURRENT EYE RESEARCH, 2008, 33 (02) :149-158
[3]  
[Anonymous], 2003, MAX PACK INS
[4]  
[Anonymous], 2007, AZASITE PACK INS
[5]  
Auw-Haedrich C, 2007, OPHTHALMOLOGE, V104, P817, DOI 10.1007/s00347-007-1608-8
[6]   Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers [J].
Chiambaretta, F. ;
Garraffo, R. ;
Elena, P. P. ;
Pouliquen, P. ;
Delval, L. ;
Rigal, D. ;
Dubray, C. ;
Goldschmidt, P. ;
Tabbara, K. ;
Cochereau, I. .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2008, 18 (01) :13-20
[7]   Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis [J].
Fadlallah, Ali ;
El Rami, Hala ;
Fahd, Daoud ;
Dunia, Ibrahim ;
Bejjani, Riad ;
Chlela, Elie ;
Waked, Naji ;
Jabbour, Elyse ;
Fahed, Sharbel .
ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2012, 75 (03) :178-182
[8]   A Phase III clinical study to evaluate the efficacy of combined azithromycin and dexamethasone in the treatment of blepharoconjunctivitis [J].
Hosseini, Kamran ;
Hutcheson, Judith ;
Lindstrom, Richard L. .
CLINICAL OPHTHALMOLOGY, 2013, 7 :2225-2234
[9]  
John T, 2008, ANN OPHTHALMOL, V40, P68
[10]   Effect of Azithromycin on Lipid Accumulation in Immortalized Human Meibomian Gland Epithelial Cells [J].
Liu, Yang ;
Kam, Wendy R. ;
Ding, Juan ;
Sullivan, David A. .
JAMA OPHTHALMOLOGY, 2014, 132 (02) :226-228